SCHEMBL772745

SCHEMBL772745

CCOC(=O)c1cnn(CCc2ccccc2)c1-c1ccncc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.55
TSHR P16473 1/20 0.49
MAPK1 P28482 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
SMN1; SMN2 Q16637 4/20 0.47
MAPT P10636 1/20 0.47
CDC7 O00311 4/20 0.47
DBF4 Q9UBU7 4/20 0.47
KMT2A Q03164 3/20 0.45
CYP19A1 P11511 2/20 0.45
HPGD P15428 3/20 0.45
NPC1 O15118 2/20 0.43
LMNA P02545 1/20 0.43
GAA P10253 1/20 0.43
CCNA2 P20248 1/20 0.43
CDK2 P24941 1/20 0.43
MEN1 O00255 1/20 0.43
KDM4E B2RXH2 1/20 0.43
RAB9A P51151 1/20 0.43
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3491679 0.81 ALDH1A1 (0.65) ALDH1A1TSHRMAPK1SMN1; SMN2KMT2A
SCHEMBL772322 0.79 ALDH1A1 (0.50) ALDH1A1MAPK1NPSR1SMN1; SMN2CDC7
SCHEMBL773601 0.79 ALDH1A1 (0.50) ALDH1A1MAPK1NPSR1SMN1; SMN2CDC7
SCHEMBL771673 0.77 LMNA (0.57) ALDH1A1MAPK1NPSR1CDC7DBF4
SCHEMBL4825828 0.76 ALDH1A1 (0.56) ALDH1A1TSHRMAPK1SMN1; SMN2KMT2A
SCHEMBL11890412 0.76 ALDH1A1 (0.71) ALDH1A1TSHRMAPK1SMN1; SMN2MAPT
SCHEMBL15750636 0.75 ALDH1A1 (0.53) ALDH1A1TSHRMAPK1NPSR1SMN1; SMN2
SCHEMBL1875999 0.74 ALDH1A1 (0.55) ALDH1A1TSHRNPSR1SMN1; SMN2MAPT
SCHEMBL5796333 0.72 CYP19A1 (0.78) ALDH1A1TSHRMAPK1SMN1; SMN2MAPT
SCHEMBL21332805 0.72 SMN1; SMN2 (0.77) ALDH1A1TSHRMAPK1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440554-B1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS MERCK SERONO SA (CH) 2016-10-05 EP disclosed
EP-2440554-B1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS MERCK SERONO SA (CH) 2016-10-05 EP disclosed
US-8802663-B2 Pyrazole oxadiazole derivatives as S1P1 agonists MERCK SERONO SA (CH) 2014-08-12 US disclosed
US-8802663-B2 Pyrazole oxadiazole derivatives as S1P1 agonists MERCK SERONO SA (CH) 2014-08-12 US disclosed
US-8802663-B2 Pyrazole oxadiazole derivatives as S1P1 agonists MERCK SERONO SA (CH) 2014-08-12 US disclosed
EP-2440554-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS Merck Serono S.A. (CH) 2012-04-18 EP disclosed
US-20120071460-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS MERCK SERONO SA (CH) 2012-03-22 US disclosed
US-20120071460-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS MERCK SERONO SA (CH) 2012-03-22 US disclosed
US-20120071460-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS MERCK SERONO SA (CH) 2012-03-22 US disclosed
WO-2010142628-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS MERCK SERONO S.A. (CH) 2010-12-16 WO disclosed
WO-2010142628-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS MERCK SERONO S.A. (CH) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071460-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS S1PR1, S1PR3, S1PR2 ALDH1A1 1615/4885TSHR 435/4885MAPK1 744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.